TREACE MEDICAL CONCEPTS, INC.
TMCINasdaqHealthcare · Surgical & Medical Instruments & Apparatus · FL · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $212.7M | $209.4M | $187.1M | $141.8M | $94.4M | $57.4M |
| Operating income | −$54.2M | −$55.7M | −$51.4M | −$34.8M | −$16.5M | $855,000 |
| Net income | −$59.0M | −$55.7M | −$49.5M | −$42.8M | −$20.6M | −$3.7M |
| Total assets | $190.6M | $217.1M | $251.9M | $159.0M | $140.8M | $41.8M |
| Total liabilities | $103.2M | $104.2M | $114.0M | $98.5M | $47.7M | $41.0M |
| Equity | $87.3M | $112.9M | $137.9M | $60.5M | $93.1M | $776,000 |
| EPS (diluted) | $-0.93 | $-0.90 | $-0.81 | $-0.77 | $-0.43 | $-0.12 |
| Shares out. | 62.6M | 61.8M | 61.2M | 54.7M | 54.2M | 37.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −25.5%
- Net margin
- −27.7%
- Return on equity
- −67.6%
- Return on assets
- −31.0%
- Return on capital (ROCE)
- −33.9%
- Liabilities / assets
- 54.2%
- Debt / equity
- 1.18×
- Book value / share
- $1.39
- Revenue growth (YoY)
- 1.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.79distress
- Accruals / assets
- −22.6%clean
- Beneish M-Score
- -3.53normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)May 15, 2026
- Bank Of America Corp /De/Passive (13G)May 14, 2026
- Gagnon Securities LlcPassive (13G)Feb 12, 2026
- William Blair Investment Management, LlcPassive (13G)Feb 9, 2026
- Morgan StanleyPassive (13G)Feb 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Treace John T.Officer — Chief Executive Officer | Jun 1, 2026 | Buy | 50,000 | $3.56 |
| Treace John T.Officer — Chief Executive Officer | May 26, 2026 | Buy | 4,508 | $2.79 |
| Bakewell John KDirector | May 19, 2026 | Grant | 30,000 | $0.00 |
| Kiernan Jane EDirector | May 19, 2026 | Grant | 30,000 | $0.00 |
| Berry Lance ADirector | May 19, 2026 | Grant | 30,000 | $0.00 |
| Jain DeeptiDirector | May 19, 2026 | Grant | 30,000 | $0.00 |
| Hamilton Lawrence WDirector | May 19, 2026 | Grant | 30,000 | $0.00 |
| Hanna BetsyDirector | May 19, 2026 | Grant | 30,000 | $0.00 |
| Treace John T.Officer — Chief Executive Officer | May 12, 2026 | Buy | 43,000 | $2.17 |
| Hair MarkOfficer — Chief Financial Officer | Apr 17, 2026 | Tax withholding | 11,547 | $0.00 |
| Hair MarkOfficer — Chief Financial Officer | Apr 1, 2026 | Grant | 100,000 | $0.00 |
| Elder Scot MichaelOfficer — Chief Legl & Comp Off, CorpSec | Mar 8, 2026 | Tax withholding | 175 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.6M | 6.2 | -8.8% |
| Apr 30, 2026 | 4.0M | 9.3 | -17.9% |
| Apr 15, 2026 | 4.8M | 3.1 | +9.4% |
| Mar 31, 2026 | 4.4M | 8.7 | +10.6% |
| Mar 13, 2026 | 4.0M | 3.1 | +8.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 20, 2026
- Results of operationsMay 8, 2026
- Results of operations · Director / officer change · Regulation FD disclosureApr 9, 2026
- Results of operationsFeb 27, 2026
- Results of operations · Regulation FD disclosureJan 13, 2026
- Entered a material agreement · Terminated a material agreement · New financial obligation · Modified shareholder rights · Regulation FD disclosure · Other material eventDec 18, 2025
- Results of operations · Director / officer changeNov 6, 2025
- Results of operationsAug 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.